Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Effexor_XR
gptkb:Venlafaxine |
| gptkbp:affects |
sleep disturbances
weight gain increased anxiety increased cholesterol emotional blunting |
| gptkbp:brand |
gptkb:Effexor
gptkb:Effexor_XR |
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
Phase IV
|
| gptkbp:contraindication |
MAO inhibitors
severe renal impairment hypersensitivity to venlafaxine |
| gptkbp:dosage_form |
75-375 mg/day
|
| gptkbp:effective_date |
gptkb:1993
|
| gptkbp:form |
tablets
capsules extended-release capsules |
| gptkbp:formulation |
gptkb:tablet
extended-release capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
Effexor
|
| gptkbp:ingredients |
gptkb:venlafaxine
C17 H19 N O2 |
| gptkbp:interacts_with |
gptkb:beer
anticoagulants serotonergic drugs |
| gptkbp:is_atype_of |
N06 A X16
|
| gptkbp:is_used_for |
social anxiety disorder
generalized anxiety disorder major depressive disorder panic disorder |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:lifespan |
5 hours
11 hours for extended-release |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Wyeth_Pharmaceuticals
|
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
dizziness
nausea insomnia constipation dry mouth sweating sexual dysfunction loss of appetite increased blood pressure |
| gptkbp:symptoms |
dizziness
fatigue headache nausea irritability |
| gptkbp:type_of |
93413-69-5
|